| pubmed-article:10086652 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10086652 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10086652 | lifeskim:mentions | umls-concept:C0040038 | lld:lifeskim |
| pubmed-article:10086652 | lifeskim:mentions | umls-concept:C0021390 | lld:lifeskim |
| pubmed-article:10086652 | lifeskim:mentions | umls-concept:C0600433 | lld:lifeskim |
| pubmed-article:10086652 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10086652 | pubmed:dateCreated | 1999-4-1 | lld:pubmed |
| pubmed-article:10086652 | pubmed:abstractText | Thromboembolic events are serious complications in patients with inflammatory bowel disease (IBD). Resistance of factor V to degradation by activated protein C (APC) is a major cause for venous thrombosis and is found in approximately 30% of patients with thromboembolism. The aim of the present study was to assess the prevalence of APC resistance and clinical risk factors in patients with IBD. | lld:pubmed |
| pubmed-article:10086652 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10086652 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10086652 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10086652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10086652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10086652 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10086652 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10086652 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10086652 | pubmed:issn | 0002-9270 | lld:pubmed |
| pubmed-article:10086652 | pubmed:author | pubmed-author:VogelsangHH | lld:pubmed |
| pubmed-article:10086652 | pubmed:author | pubmed-author:NovacekGG | lld:pubmed |
| pubmed-article:10086652 | pubmed:author | pubmed-author:KapiotisSS | lld:pubmed |
| pubmed-article:10086652 | pubmed:author | pubmed-author:Katzenschlage... | lld:pubmed |
| pubmed-article:10086652 | pubmed:author | pubmed-author:SpeiserWW | lld:pubmed |
| pubmed-article:10086652 | pubmed:author | pubmed-author:MiehslerWW | lld:pubmed |
| pubmed-article:10086652 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10086652 | pubmed:volume | 94 | lld:pubmed |
| pubmed-article:10086652 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10086652 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10086652 | pubmed:pagination | 685-90 | lld:pubmed |
| pubmed-article:10086652 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:meshHeading | pubmed-meshheading:10086652... | lld:pubmed |
| pubmed-article:10086652 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10086652 | pubmed:articleTitle | Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. | lld:pubmed |
| pubmed-article:10086652 | pubmed:affiliation | Department of Internal Medicine IV, Clinical Institute of Medical and Chemical Laboratory Diagnostics, University of Vienna, Austria. | lld:pubmed |
| pubmed-article:10086652 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10086652 | lld:pubmed |
